Tivozanib in Clear-Cell RCC: Adverse Event Management Strategies

News
Video

Perspectives on the adverse events and management of tivozanib, covering common and serious toxicities with an emphasis on a multidisciplinary approach to optimize patient care and treatment benefits.

Summary:

In discussing adverse events associated with tivozanib, one speaker highlights its favorable adverse effect profile, attributing most adverse effects to specific VEGF toxicities rather than off-target effects. Hypertension remains a predominant adverse event, accompanied by manageable occurrences of diarrhea, nausea, fatigue, and mucositis. However, one panelist underscores the potential serious but uncommon toxicities related to VEGF tyrosine kinase inhibitors (TKIs), particularly cardiovascular complications like cardiac failure, ischemic heart disease, thromboembolism, and wound healing issues.

To manage these adverse effects, panelists emphasize the importance of comprehensive patient care. Addressing fatigue involves assessing sleep quality, physical activity, and nutrition. If fatigue persists, a reevaluation of the drug dose and a short treatment break may be considered. Hand-foot syndrome prevention is crucial, involving the prophylactic application of urea-based creams and, if necessary, high-dose topical steroids or treatment breaks.

Multidisciplinary collaboration is crucial in managing adverse effects. One speaker suggests involving nephrology colleagues for proteinuria concerns, dermatology experts for persistent hand-foot syndrome, and cardiology specialists for blood pressure management. Blood pressure monitoring at home, especially for patients with baseline hypertension, allows early intervention with medications like ACE inhibitors or angiotensin receptor blockers. This multidisciplinary approach optimizes adverse effect management, potentially enabling patients to stay on treatment comfortably for extended periods and derive maximal treatment benefits.

Summary is AI-generated and reviewed by Cancer Network editorial staff.

Recent Videos
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
Blood-based markers of note in kidney cancer prognosis include circulating tumor DNA and proteomic markers, according to Michael B. Atkins, MD.
Clinical trials still have a role in improving outcomes with immunotherapy among those with kidney cancer.
Current research initiatives in the kidney cancer field include exploring anti–PD-1, anti–LAG-3, and anti–CTLA-4 combination regimens.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Related Content